NCT00556348

Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Instituto de Olhos de Goiania · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.

Detailed description

We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	bevacizumab	1.25mg

Timeline

• Start date: 2005-11-01
• Primary completion: 2007-10-01
• Completion: 2008-11-01
• First posted: 2007-11-12
• Last updated: 2011-11-22